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Abstract
Since 2004 it become clear that atypical bovine spongiform encephalopthies (BSEs) exist in cattle. Whenever their detection
has relied on active surveillance plans implemented in Europe since 2001 by rapid tests, the overall and inter-laboratory
performance of these diagnostic systems in the detection of the atypical strains has not been studied thoroughly to date. To
fill this gap, the present study reports on the analytical sensitivity of the EU-approved rapid tests for atypical L- and H-type
and classical BSE in parallel. Each test was challenged with two dilution series, one created from a positive pool of the three
BSE forms according to the EURL standard method of homogenate preparation (50% w/v) and the other as per the test kit
manufacturer’s instructions. Multilevel logistic models and simple logistic models with the rapid test as the only covariate
were fitted for each BSE form analyzed as directed by the test manufacturer’s dilution protocol. The same schemes, but
excluding the BSE type, were then applied to compare test performance under the manufacturer’s versus the water
protocol. The IDEXX HerdChek H BSE-scrapie short protocol test showed the highest sensitivity for all BSE forms. The IDEXXH
HerdChek BSE-scrapie ultra short protocol, the PrionicsH - Check WESTERN and the AJ RoboscreenH BetaPrion tests showed
similar sensitivities, followed by the RocheH PrionScreen, the Bio-RadH TeSeETM SAP and the PrionicsH - Check PrioSTRIP in
descending order of analytical sensitivity. Despite these differences, the limit of detection of all seven rapid tests against the
different classes of material set within a 2 log10 range of the best-performing test, thus meeting the European Food Safety
Authority requirement for BSE surveillance purposes. These findings indicate that not many atypical cases would have been
missed surveillance since 2001 which is important for further epidemiological interpretations of the sporadic character of
atypical forms.
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Introduction
Transmissible spongiform encephalopathies (TSEs) or prion diseases
include a group of progressive, neurodegenerative as yet untreat-
able disorders affecting several mammalian species, including
Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform
encephalopathy (BSE) in cattle and scrapie in small ruminants.
TSEs are characterized by the concentration of an anomalous
isoform (PrPRes) of the natural prion protein (PrPc) in the central
nervous system (CNS) and peripheral tissues. PrPres differs from
PrPc in its aggregated state and partial protease resistance. These
characteristics are exploited by the majority of the methods
currently used for TSE diagnosis. The protease resistant disease
related PrP entity, varies in its extent of degradation by proteinase
K (PK) which is influenced by the strain-dependent conforma-
tional variations of the secondary and tertiary structure of PrPres.
In different TSE strains, the pathological prion protein displays
disease-specific features such as different cleavage sites after
proteolytic treatment, glycosylation profile, and deposition pat-
terns, which make strain identification possible [1].
The existence of different BSE strains was discovered in 2004.
The classical form (C-BSE) coexists with the atypical H-type BSE
(H-BSE) originally described in France [2] and the L-type BSE (L-
BSE), also known as bovine amyloidotic spongiform encephalop-
athy (BASE), an unusual form of BSE first identified in Italy [3].
Their diagnostic differentiation is based mainly on the molecular
features of the PrPres identified by Western blot analysis. After PK
digestion, PrPres shows a triplet of non-, mono-, and diglycoforms,
which, while expressing their quantitative ratio and migration
positions, peculiarly typify the original BSE strain [4]. H- and L-
BSE have a higher or a lower discernible molecular mass of
unglycosylated PrPres, respectively, at Western blot analysis; in
addition, L- BSE has smaller proportion of diglycosylated PrPres
with levels between 40–55% than C-BSE where values range
between 60–80%. Subsequently, occurrence of the two atypical
forms to several European countries, Japan and North America
has been reported. The origin of different BSE forms is still cryptic.
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C-BSE, which was isolated during the epizootic disease, was
postulated to have occurred after the recycling of a scrapie agent
insufficiently deactivated in destructor plants [5,6]. However, this
has been questioned after the detection of atypical BSE forms that
seem to occur spontaneously in older cattle [7] and that, under
certain circumstances, are able to change their biochemical
properties into those of classical BSE. The accidental use of
bovine material derived from an animal that had succumbed to a
spontaneous form of BSE in the feed and food production may
therefore also have been the origin of the BSE crisis. Such
hypothesis seems to be also compatible with the peculiar
distribution by year of birth of cattle affected by atypical BSEs,
in comparison to bovines affected by C-type BSE observed in
France [8]. Moreover, it has been shown in several transmission
experiments to primates [9,10] and in human and bovine PrP
transgenic mice [11,12] that L-type BSE seems to have a higher
zoonotic potential than C-type BSE. The use of rapid tests that are
able to reliably detect such cases is therefore crucial in the frame of
the protection of the consumer from an accidental exposure to the
BSE agent.
Until 1999 EU surveillance systems for bovine spongiform
encephalopathy (BSE) were primarily passive, i.e. relying on the
examination of diseased adult cattle showing clinical signs reported
to the veterinary authorities, in compliance with the Decision 98/
272/EC which modifies Decision 94/474/EC [13]. Brains were
examined by histopathology and immunhistochemistry for PrPres
identification. Rapid molecular diagnostic assays became officially
available in the late 1990s. With the enforcement of Regulation
(EC) No. 999/2001 [14] the use of rapid tests became mandatory:
a large number of countries subsequently detected the first BSE
cases.
To provide dependable tools for an active surveillance system,
in 1999 the European Commission (EC) carried out the first
scientific evaluation of four new rapid post mortem BSE tests to
assess their diagnostic accuracy and analytical sensitivity on brain
tissue from clinically affected bovines [15]. Subsequent EU
validation exercises enhanced the estimating parameters, including
test robustness on autolyzed samples and testing of negative field
samples to address the test specificity and to simulate routine
activity [16,17,18].
To date, the EC has assessed 19 rapid tests in the frame of three
‘‘successive’’ evaluations and approved 9 for survey purposes [19].
In 2009 the Community Reference Laboratory (EURL) for
TSEs assessed the analytical sensitivity of all the currently
approved TSE rapid tests to determine their continued suitability
for active surveillance plans [20]. The analytical sensitivity study
was then evaluated by the European Food Safety Authority
(EFSA) [21,22] on the basis of current EFSA requirements for the
evaluation of TSE rapid post mortem tests [23].
In that context, the lowest limit of detection (LOD) of rapid tests
approved for the diagnosis of TSEs in bovines was assessed. The
pre-prepared positive and negative dilution series (EURL protocol)
were compared with the manufacturer’s dilution series. The rapid
tests with a LOD poorer than 2 log10 as compared to the best-
performing assay could not be recommended for use in the frame
of BSE monitoring in cattle and TSE in small ruminants within
the EU.
At same time, the BIOHAZ Panel recommended that a similar
study should have been conducted with regard to the other TSE
strains. Furthermore, because experimental transmission of
atypical BSE prions suggests that they might be more insidious
than classical BSE [24], the assessment of approved rapid-test
performance on detecting atypical BSE strains remains a priority.
The aim of this study was to compare the analytical sensitivity of
all presently EU-approved rapid post mortem tests for the detection
of atypical BSE forms in bovines by assessing their lower LOD
against atypical L- and H-type BSE. The outcome will be of
interest for the interpretation of epidemiological surveillance data
of all three BSE types.
Materials and Methods
Study Design
Consistent with the methodology of the EFSA analytical
sensitivity study, the strategy of the Italian TSE National
Reference Laboratory (NRL) was to compare the performance
of all approved rapid tests against the same sample pools. Thus,
the test results could be directly compared and their performance
ranked according to their respective LOD.
Each test was challenged with decreasing amounts of confirmed
BSE-positive material in a consistent background of negative
material prepared following two protocols: the one using the
EURL standard method of homogenate preparation (50% w/v
protocol) [23] and the other as directed by the test kit
manufacturer’s instructions. This was done to permit comparison
between the two preparation protocols.
The study design was set up to account for several confounders
(e.g., the operator, the day of the test, plates, etc.). Factors were
controlled by minimizing variability (e.g., all tests were performed
by only two operators) and fitting multilevel logistic models in
which the confounders were set as random or fixed effects
[25,26,27].
The first step was a basic descriptive analysis. The second
involved only the manufacturer’s protocol, and a multilevel logistic
model was fitted for each BSE type in order to compare test kit
performance. The date of testing execution constituted the first
level of the models (level 1); replicated crossover and nesting of the
plates were the second level (level 2). The intraclass correlation
coefficient (ICC) of the replicates obtained from these models
allowed us to verify that their residual variance was due only to the
replicates [25,26,27]. In this case, when the number of positive
replicates was monotone decreasing in the dilutions, we could
neglect the fixed effect of the dilution and focus instead on the
effect of the different test kits. In the third step, simple logistic
models [28,29] were fitted with the specific test kit as the only
covariate.
Finally, the test results obtained under the two preparation
protocols were compared. As mentioned, we fitted the multilevel
logistic models not referring to each BSE type but instead to each
test kit. Seven simple logistic models [28,29] one for each test,
were then fitted: the interaction between BSE type and protocol
was the only covariate in the model.
Tissue Background
Briefly, atypical L-BSE tissue was obtained from two Italian
field cases. The atypical H-BSE tissue pool was provided to the
Italian NRL by the Friedrich-Loeffler-Institut (FLI) (Germany)
and originated from German calves experimentally inoculated
intracranially [24]. Two C-BSE pools were included in the study,
one strongly reacting at confirmatory Western blot, the second
weakly. This was done in order to have reference data on known
matrices for the comparison of unexplored results with atypical
BSE. The strong C-BSE type tissue included a pool of five Dutch
regularly slaughtered field cases (collected and tested in the frame
of statutory BSE surveillance plane) provided by Central
Veterinary Institute of Wageningen UR (CVI). The weak C-
BSE tissue was a mixture of two Italian natural cases. All positive
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tissues originated from brain stem area and were confirmed by
discriminatory Western blot analysis [4]. The negative tissue was
created from 30 bovine brainstems randomly selected from Italian
slaughtered surveillance samples which had tested negative at the
IDEXXH HerdCheck BSE-scrapie ultra short protocol test [30] and
confirmatory Western blot.
All details pertaining to sample origin were recorded.
Preparation of Diagnostic Test Material
To ensure that the samples would be homogeneous, they were
prepared using the Veterinary Laboratory Agency (VLA) standard
methods for TSE QA sample production (Veterinary Laboratory
Agency, Standard Operating Procedure, ‘‘Instruction for the
homogenisation and dilution of brainstem for preparation of QA
Samples’’ – personal communication).
Accordingly, four CNS tissue pools (L, H, C strong, and C
weak) were prepared from L-BSE-positive, H-BSE-positive, C-
BSE strong and C-BSE weak positive tissues, respectively. The
100% CNS tissues were trimmed, pooled, mildly minced with
scalpels, and then treated with a low-speed hand-held homoge-
nizing unit for 30 s. A negative pool was prepared as described
above. Each BSE-positive macerate pool was diluted in pre-
homogenized negative tissue to obtain 2 base logarithm dilutions
series down to 1:1024. As the 1:1024 dilution of the C-BSE strong
pool tested positive at the IDEXXH HerdCheck BSE-scrapie short
protocol, further 1:2048 and 1:4096 dilutions of the same tissue were
investigated, with negative results.
To set up the dilution series, one half of the BSE-positive pools
was prepared under the EURL homogenization protocol in
nuclease-free water (50% w/v) using a low-speed hand-held
homogenizing unit for a total of 90 s in three successive
treatments. Each dilution underwent a final homogenization cycle
to ensure the preparation was mixed thoroughly. All the
homogenates were aliquoted into test-specific pre-labelled grinding
tubes as directed by the manufacturer’s instructions and stored at
220uC.
The other half of the BSE-positive and negative starting tissue
pools was distributed in the manufacturer’s tissue-disruption
supports for the different test kits and then immediately submitted
to the specific protocols as per the manufacturer’s instructions.
Each dilution was tested in triplicate by each rapid test. The test
panel consisted of 150 aliquots, with 30 samples per pool, for each
dilution protocol.
Testing Exercise
The tests included in the study were those approved according
to Regulation (EC) No. 999/2001 amended by Regulation 162/
2009. Enfer Scientific [31] declined to participate in the study.
The PrionicsH - Check LIA BSE Antigen Test Kit [32] had been
withdrawn from the market at the time the study was conducted.
A unique batch of each rapid test specifically provided for this
study by the manufacturers largely before the relative expiring
date was used for all the analyses. One rapid test was performed
per day and all the dilution series were tested in triplicate. One out
of three positive results interpreted according to the test
specifications was selected as the criterion for judging the overall
result as positive. For the evaluation of the PrionicsH - Check
WESTERN [33], the samples were considered positive if they
exhibited a signal with a three-band pattern. A more diffuse
pattern of PrPres with the top band clearly visible, as reported by
the manufacturer, was considered positive as well.
The laboratory test exercise was completed within 15 days from
the starting point of generating and freezing the aliquots.
Results
The analyses of the different BSE samples – C-type strong, C-
type weak, H-type and L-type – under both the EURL protocol or
the manufacturers’ protocol indicated that in principle, all tests
were able to detect the different types of BSE though at different
sensitivity (Table 1).
The ability of the rapid tests to identify positive replicates clearly
differed between the tests when increasing dilutions were
compared within the manufacturers’ protocol and under the
EURL 50% w/v protocol. Under the manufacturer’s dilution
protocol, the sensitivity of the IDEXXH HerdCheck BSE-scrapie short
protocol test for all BSE types was higher than that of the other rapid
tests. The sensitivity of the IDEXXH HerdCheck BSE-scrapie ultra short
protocol, PrionicsH - Check WESTERN, and AJ RoboscreenH BetaPrion
[34] was similar, followed in decreasing order by the RocheH
PrionScreen [35] Bio-RadH TeSeETM SAP [36] and PrionicsH - Check
PrioSTRIP [37], the last two of which displayed the lowest
analytical sensitivity, notably for L-BSE.
The multilevel models fitted in the second step of the statistical
analysis confirmed that the residual variance was almost entirely
due to the replicates. For all BSE types, the ICC of the replicates
was higher than 0.99. Therefore, apart from a few exceptions, it
was assumed that the three replicates for each dilution would have
the same result, whereupon a simplified logistic model was
adopted. The IDEXXH HerdCheck BSE-scrapie short protocol was taken
as the reference test, as it provided the highest analytical sensitivity
for all BSE forms.
The logistic models showed that a loss of sensitivity up to two
dilutions lower than the best-performing test was not statistically
significant. Testing with the C-BSE strong pool showed that only
the IDEXXH HerdCheck BSE-scrapie ultra short protocol test compared
favourably with the IDEXXH HerdCheck BSE-scrapie short protocol test;
while the sensitivity of the AJ RoboscreenH BetaPrion, IDEXXH
HerdCheck BSE-scrapie ultra short protocol, PrionicsH - Check WESTERN
for detecting the other BSE types was not statistically different
from that of the reference test.
To further discriminate between the quality of performance of
the different test systems, logistic models were applied on the data
obtained. On the basis of the odds ratio (OR) magnitude, each test
can be ranked using the IDEXXH HerdCheck BSE-scrapie short protocol
as reference test and it can be concluded that a higher OR is
related to higher sensitivity. Ranking obtained under the
manufacturer’s protocol did not differ from that obtained under
the water protocol (Figure 1).
Comparison of test performance under the two dilution
protocols based on the descriptive analysis (Table 1) showed that
all seven tests had a higher analytical sensitivity for the BSE-
positive samples prepared under the manufacturer’s protocol than
those prepared as per the water protocol for all BSE types, except
for H-BSE, toward which the tests performed generally better with
the 50% w/v homogenates.
The same scheme to compare the tests under the manufactur-
ers’ protocol was then applied to compare their performance
under the water protocol. A simple logistic model was fitted for
each test. All seven rapid tests performed better under the
manufacturers’ dilution protocol than under the 50% w/v
protocol (Figure 2), as already suggested by the descriptive
analysis, however, upon the least approach, this result appeared
to be statistically significant only for the AJ RoboscreenH BetaPrion
and the Bio-RadH TeSeETM SAP kits.
Assessment of test specificity was not within the scope of this
study; nevertheless, appropriate BSE-negative tissue amounts
tested on each test platform displayed negative results.
EU-Approved Rapid Tests Detect Atypical BSE
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Figure 1. Test performance compared to the IDEXXH HerdCheck BSE-scrapie short protocol. The vertical axis reports the different rapid tests
challenged. The horizontal axis reflects the odds ratio magnitude using IDEXXH HerdCheck BSE-scrapie short protocol as reference test. Panels A, B, C,
D (left column) report the results obtained under the w/v protocol; panels E, F, G, H (right column) display the results under the manufacturers’
instructions. BSE forms studied: panels A, E: strong C-type; panels B, F: weak C-type; panels C, G: H-type; panels D, H: L-type. All the weak C type water
dilutions series tested negative with Bio-RadH TeSeETM SAP (notably, the optical densities were for all the three replicates of the 1:2 dilution just under
the cut-off value), thereby, the odd ratio could not be calculated (Subfigure B).
doi:10.1371/journal.pone.0043133.g001
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Discussion
In this study we have evaluated the analytical sensitivity of
approved rapid tests for the current known atypical BSEs
detection. It is to be noted that Seuberlich et al. [38] raised the
possibility that a new prion disease not previously encountered and
distinct from the known types of BSEs exists. Nevertheless, the
information is really limited and the puzzle of the different
observations has still to be assembled, considering that the results
described remind the features of poorly digested normal PrP
(known as the physiologically C2 fragment of PrP [39,40]).
Referring to the tissues origin, is to be remarked that the
investigated H-BSE tissues originated from intracranially chal-
lenged cattle, whereas the three other forms derived from field
cases. Nevertheless, recent studies showed that biochemical and
histopathological features of experimental H-type BSE animals
were identical to that found with field H-type [12,24,41].
According to our results, all tests were able to detect both H-
and L-BSE types at a 1:16 dilution prepared as directed by the
manufacturer’s instructions, with the same performance as for
classical BSE.
The LOD varied across the tests. The IDEXXH HerdCheck BSE-
scrapie short protocol showed the highest analytical sensitivity, as
previously reported in a EURL study on classical BSE [21]. The
performance of the AJ RoboscreenH BetaPrion, IDEXXH HerdCheck
BSE-scrapie ultra short protocol, and PrionicsH - Check WESTERN
compared favourably with one another at our statistical analysis.
The PrionicsH - Check PrioSTRIP, Bio-RadH TeSeETM SAP and RocheH
PrionScreen tests showed the lowest sensitivities for all the BSE types
analyzed. These results were confirmed also using other explor-
ative statistical approaches (e.g., Poisson models for number of
positive replicates, receiver operating characteristic [ROC] curves)
which we had initially applied (results not reported).
The analytical sensitivity of the tests was investigated in
accordance with the requirements set by the relevant evaluation
protocols established by the European Commission, the SSC and
EFSA, using serial dilutions of sample replicates.
Test differences between the last positive dilutions of weak and
strong C-BSE samples varies among the different systems from two
to four factors (2 base logarithm) for buffer dilutions and from two
to five factors for water dilutions. In this context, the different tests
showed parallel results between the dilutions prepared following
the two protocols. The dynamic range of each rapid test or rather
the concentration range of PrPres that results in a change in
response is a specific peculiarity of each diagnostic system.
The rate of conversion of substrate to coloured product should
be proportional to the amount of PrPres within the well, but there
are many limits to this depending on the analyte itself, that tends to
aggregate rapidly in solution, and on the combination of methods
and materials used within the test kits other than on the
equipments.
A gradual stratification of the signal represents a surplus value for
TSE rapid assays.
In our study, the Bio-RadH TeSeETM SAP test could surprisingly
detect only the 1:2 dilution when challenged with positive C BSE
weak samples. A loss of analytical sensitivity for this test was
observed also during the active surveillance activity carried out
from 2004 to 2008 by the Italian Reference Center for TSEs
applying Bio-RadH TeSeETM test. In that context, a National batch
testing was performed on every new batch prior to commercial-
ization to provide reassurance that BSE rapid test kits were fit for
the survey purpose. As a consequence, distribution of some kit
batches was precluded because of the lack of signal showed on
positive reference samples. Further to the unexpected poor
performance of Bio-RadH TeSeETM within this study even after
test repetition, the same Bio-RadH homogenate sample set,
according to previous studies in which its suitability for the
IDEXX test was shown, was challenged with the last test revealing
signals miming the ones reported for IDEXX test (data not shown).
Figure 2. Comparison of test performance under the manufacturer’s dilution protocol versus the 50% w/v protocol. The vertical axis
reports the different rapid tests challenged. The horizontal axis reflects the odds ratio magnitude.
doi:10.1371/journal.pone.0043133.g002
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The question of whether the specific kit batch affected the test
performance is of concern, but it is noteworthy that all producers
were asked to provide a kit for this evaluation. Thereby, our results
represent a picture of the kits available on the market.
The seven simple logistic models showed a meaningful
difference between the dilution protocols only for the AJ
RoboscreenH BetaPrion and Bio-RadH TeSeETM SAP. The lower
bounds of the 95% confidence intervals for the RocheH PrionScreen
and PrionicsH - Check WESTERN tests approached 1 (0.9528 and
0.9755, respectively); for the remaining tests, there was no
statistical evidence of a higher test sensitivity between the
manufacturer’s dilution protocol and the 50% w/v protocol
(Figure 2).
Whenever in order to evaluate the field performances of BSE
rapid post mortem tests the manufacturers’ protocol represents the
term of reference, the relevance of water dilution-based results
relies on the specific Annex X of Regulation (EC) 999/2001
requirements. NRLs for TSE periodically have to verify national
diagnostic standards and methods by means of comparative trials.
The objectives are to monitor national rapid test activity and to
demonstrate to the EC that the rapid surveillance system is
effective. EURL itself annually verifies the interlaboratory
agreement of the rapid systems used by the NRLs.
As previously reported in the EURL study [20], the analytical
sensitivity values obtained under the 50% w/v protocol were from
one to three dilutions inferior to those obtained under the specific
homogenization protocol. For all the tests except one, the
discrepancies between the two modes of dilutions were similar
whatever the sample tested. Particularly with the Bio-Rad test the
strong positive C -BSE sample was four factors lower when the
water protocol was applied. Anyway, this is congruent with the
EFSA 2009 results [21], where the discrepancy set at three
logarithms. This difference needs to be taken into account when
organizing ring trials, during which a less sensitive test could be
penalized.
To rule out a possible decrement of the signal related to the
storage of the water aliquots, and because of the scarcity of
atypical BSE material, the laboratory test exercise was completed
within a 15-day period. This precautionary approach was taken as
no data exist on the stability of atypical BSE homogenates,
whereas differences in stability have been observed for atypical
versus classical scrapie [21,42,43,44]. Further, as it is indeed known
that the results of some tests can lapse while approaching the
expiring date of kit batches, the kits provided for the evaluation
were expected to expire from three to six months after the date of
testing. Table S1 lists the kit batches used, the expiring dates and
the days of testing.
With regard to the homogeneity of serial dilutions, as PrPres is
amyloidogenic, the fibrils tend to aggregate in solution [45], thus
potentially hindering a real homogeneity of dilution series. In our
study, the ICC of the replicates was higher than 0.99. This ensured
that, whenever the amounts of BSE tissues available were
extremely limited, the material tested was homogeneous.
When considering the working principle of rapid tests,
summarized in the Text S1, all approved tests include a PK
digestion step to unmask cryptic epitopes, except for the IDEXX
HerdChekH BSE-scrapie EIA, which relies on conformational
detection technology using a specific aggregate specific capture
ligand on a dextran polymer (Seprion ligand technology,
Microsens Biotechnologies, London, UK) [46]. The severe effects
of proteinase K (PK) in digesting atypical PrPres are well known.
Depending on the PK concentration, signal loss after atypical
BSE-related PrPres PK digestion varies from less than 20% for the
C-type isolates to more than 50% for both L- and H-type BSE
tissues [4]. This could be the reason for the higher sensitivity of the
IDEXX test in detecting atypical BSEs compared to the others.
However, the type of detergent used in homogenates and the type
of TSE strain used do affect the extent of PrPres degradation, and
this remains a matter of further study [47].
With regard to the interpretation of results, five of the rapid tests
in this study are based on semi-quantitative ELISA methods that
produce a qualitative result relative to a cut-off value. To minimize
subjectivity, the study’s PrionicsH - Check PrioSTRIP results were
interpreted with the use of the computerized PrioSCANH software,
although visual interpretation by two independent readers was also
validated. The PrionicsH - Check Western is both a qualitative and
quantitative test, as it distinguishes PrPres in non-, mono-, and
diglycoforms while expressing their respective quantitative ratio
and migration positions. The diagnostic criteria for positive results
are based on the exhibition of a three-band signal, the top one
corresponding to a protein with an approximate molecular weight
of 30 kD. Signal intensity decreases from top to bottom, but the
higher band should be clearly visible immediately under the PK
band. Significant blot images of atypical BSE dilution series
obtained on in the frame of this study are presented in the Figure
S1. In addition, extremely weak samples, notably for atypical BSE
strains, can vary in their conventional blot pattern that fit positive
criteria. Glycoform separation on the Sodium Dodecyl Sulphate
PolyAcrylamide gel by electrophoresis causes the PrPres signal to thin
out along the migration line rather than concentrate in a narrow
area, as occurs with ELISA and immunochromatographic
methods. This means that if the relative non-, mono-, and
diglycoform immunoreactivity ratios of L-BSE are taken as
corresponding roughly to 39%, 35%, and 26% [48], the blot
signal characterizing the last tissue ratio meeting the non-negative
criteria generates from only 39% of the total prion protein on the
migration line. Despite this, the PrionicsH - Check Western was found
to be among the more sensitive systems, indicating that the
interpretation of a specific PrPres marker by an expert reader can
increase the test’s sensitivity.
In conclusion, despite the evidence of clear differences in
relative analytical sensitivity, the LOD of all seven rapid tests
included in this study, against all the classes of material used, was
within a 2 log10 range of the best-performing test, thus meeting
EFSA criteria for rapid tests for BSE monitoring.
No certain conclusions on the field of diagnostic performance of
these rapid-test kits can be drawn from our results on their
analytical sensitivity, as the two parameters are not directly linked,
anyway samples from animals exhibiting subclinical signs [24],
could be expected to behave similarly to extremely diluted CNS
tissues used in analytical sensitivity studies.
The outcome of this study endorses the current epidemiological
follow up and interpretation of all three BSE forms prevalence
[49,50] and means that for epidemiological studies the data
obtained in the different countries and regions of EU can be
considered equally, as plausibly, most stronger atypical cases have
been detected by the different rapid tests.
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